Jeff Jonas News
-
Bristol-Myers Squibb Co. fell the most in more than eight months after slow sales of existing products trumped investors’ interest in new cancer and hepatitis C drugs the company has in development.
-
Johnson & Johnson, the world’s biggest maker of health-care products, reported first-quarter earnings that beat analysts’ estimates as new drugs and the acquisition of Synthes Inc. boosted sales.
-
Senator Charles E. Grassley said he will investigate how an investor services firm specializing in so-called political intelligence got early word of a Medicare- rate decision that led to a surge in health insurer stocks.
-
Covidien Plc., a maker of surgical products and drugs, plans to spin off its pharmaceuticals division into a separate company that would be better able to compete in the growing pain-management area.
-
Jeff Jonas, an analyst at Gabelli & Co., says he recommends shares of Bristol-Myers Squibb and Watson Pharmaceuticals. Jonas talks with Bloomberg's Ken Prewitt, Tom Keene and Sara Eisen on Bloomberg Radio's "Bloomberg Surveillance."
-
Bristol-Myers Squibb Co.’s fourth- quarter earnings beat analysts’ estimates after the company took a tax benefit from a hepatitis C drug that failed last year.
-
McKesson Corp., the largest U.S. drug distributor, agreed to acquire PSS World Medical Inc. for about $1.62 billion to expand in medical supplies and services.
-
Johnson & Johnson plans to leave the market for the drug-coated heart stents it pioneered, in a restructuring that will close two factories and cut as many as 1,000 jobs.
-
Johnson & Johnson , the world’s second-biggest seller of health products, increased its annual earnings forecast after quarterly profit beat estimates on drug sales and a weak dollar. The shares rose the most since 2008.
-
Watson Pharmaceuticals Inc. Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future “‘transformational” purchase as he reshapes the generic-drug maker.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page